title: Pharmaco- and therapygenetic aspects in the treatment of anxiety disorders beyond the serotonergic system: a brief review.
abstract: Anxiety disorders (ADs) are among the most frequent psychiatric disorders. In addition, key features of ADs include that they are among the earliest mental disorders to manifest and that their first specific treatment frequently occurs several years after the onset of symptoms. Although the heritability of anxiety disorders is well known, the genetic determination of response to different modalities (psycho- or pharmacotherapy) used in treatment of patients with ADs is lesser investigated. Several studies focused on the role of serotonergic genes in the etiopathology and pharmacotherapy of anxiety disorders, however, less attention was paid to variants of other genes. In this review we focus on the cytochrome P 450, BDNF, COMT, MAOA, EAA-3 transporter, dopamine transporter and dopamine receptor gene polymorphisms and their effects with respect to the pharmacogenetics of anxiety disorders. We discuss the current knowledge on pharmacogenetic/therapygenetic aspects of anxiety disorders beyond the serotonergic system.
authors.affiliation: Department of Clinical and Theoretical Mental Health, Kútvölgyi Clinical Center, Semmelweis University, 1125 Budapest, Hungary.
authors.forename: Gabor
authors.initials: G
authors.lastname: Faludi
authors.forename: Xenia
authors.initials: X
authors.lastname: Gonda
authors.forename: Gyorgy
authors.initials: G
authors.lastname: Bagdy
authors.forename: Peter
authors.initials: P
authors.lastname: Dome
mesh_terms: D014151:Anti-Anxiety Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D019208:Brain-Derived Neurotrophic Factor / Q000235:genetics; D002394:Catechol O-Methyltransferase / Q000235:genetics; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D050483:Dopamine Plasma Membrane Transport Proteins / Q000235:genetics; D050580:Excitatory Amino Acid Transporter 3 / Q000235:genetics; D020022:Genetic Predisposition to Disease; D006801:Humans; D008995:Monoamine Oxidase / Q000235:genetics; D010597:Pharmacogenetics / Q000639:trends; D011110:Polymorphism, Genetic; D011954:Receptors, Dopamine / Q000235:genetics; D011985:Receptors, Serotonin / Q000187:drug effects; D012701:Serotonin / Q000378:metabolism; D018490:Serotonin Agents / Q000494:pharmacology
chemical_list: D014151:Anti-Anxiety Agents; D019208:Brain-Derived Neurotrophic Factor; D050483:Dopamine Plasma Membrane Transport Proteins; D050580:Excitatory Amino Acid Transporter 3; D011954:Receptors, Dopamine; D011985:Receptors, Serotonin; C493400:SLC1A1 protein, human; D018490:Serotonin Agents; D012701:Serotonin; C579455:BDNF protein, human; D003577:Cytochrome P-450 Enzyme System; D008995:Monoamine Oxidase; C579458:monoamine oxidase A, human; D002394:Catechol O-Methyltransferase